JW LifescienceJW생명과학
234080 · KOSPI · ₩234080 · JW생명과학
₩10,420▼ ₩100 (0.95%)End-of-day · Oct 26, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩258B | ₩222B | ₩207B | ₩189B | ₩170B |
| Cost of sales | ₩186B | ₩165B | ₩154B | ₩141B | ₩121B |
| Gross profit | ₩72B | ₩58B | ₩52B | ₩48B | ₩49B |
| Operating income | ₩33B | ₩36B | ₩31B | ₩27B | ₩28B |
| Net income | ₩29B | ₩44B | ₩28B | ₩15B | ₩12B |
| Net income to shareholders | ₩29B | ₩44B | ₩28B | ₩15B | ₩12B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩318B | ₩325B | ₩256B | ₩253B | ₩219B |
| Current assets | ₩88B | ₩106B | ₩108B | ₩105B | ₩64B |
| Cash and equivalents | ₩8.4B | ₩7.5B | ₩20B | ₩3.9B | ₩4.9B |
| Total liabilities | ₩98B | ₩125B | ₩96B | ₩113B | ₩88B |
| Current liabilities | ₩84B | ₩80B | ₩94B | ₩80B | ₩84B |
| Borrowings | ₩49B | ₩40B | ₩31B | ₩67B | ₩46B |
| Total equity | ₩221B | ₩200B | ₩159B | ₩140B | ₩131B |
| Shareholders' equity | ₩221B | ₩200B | ₩159B | ₩140B | ₩131B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩41B | ₩51B | ₩38B | ₩14B | ₩30B |
| Capital spending | ₩13B | ₩10B | ₩8.2B | ₩8.1B | ₩19B |
| Free cash flow | ₩28B | ₩40B | ₩29B | ₩6B | ₩11B |
| Dividends paid | ₩7.7B | ₩7.7B | −₩7.7B | ₩7.7B | ₩7.9B |
Consolidated where available. Amounts in won.
Also known as: JW Lifescience / JW생명과학 / 234080 / KRX:234080
Source: KRX statistical information